Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients - Wikidata - wikimedia - TriplyDB

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

http://www.wikidata.org/entity/Q33809458

about

Mechanisms underlying skin disorders induced by EGFR inhibitors Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS Pharmacologic resistance in colorectal cancer: a review Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer Treatment Individualization in Colorectal Cancer PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics.Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer.A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3 The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis.Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome.Can we accurately report PTEN status in advanced colorectal cancer?PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer.Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients.Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer Biomarker-based selection of therapy for colorectal cancer.Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.Role of targeted agents in metastatic colorectal cancer.Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories.Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.Gene expression profile analysis of dbpA knockdown in colorectal cancer cells.Panitumumab for the treatment of metastatic colorectal cancer: a review.

P2860

Q26745689-FDDDE0F6-470C-46D8-846E-DB29C40D46B6 Q26766535-33AA420B-2859-443F-A895-1EB458D15A97 Q26769850-77E7B732-BFCD-4CB0-AE96-B8CF1ADBB65A Q26769958-81C99F82-A44B-48C6-B1A0-49A2191AF30E Q26776215-A88A77C9-C5A8-4983-9263-62EE487C6FA6 Q26992267-1E1BA9CE-C33B-4DC4-A8E3-EF38A990BA9E Q27852062-968BEE75-FADB-4175-9439-11AD55A3862B Q27852105-193441B1-F5AF-444A-A4E2-3FA4B1BDFCD8 Q27852988-B3B37089-424F-46D3-B22B-548B0A478240 Q27853131-A67E07FF-02D6-463E-868C-A5E81116AB07 Q30248900-12F3533B-697A-4663-A19F-DCEA4A121A18 Q30862367-D82651DE-C040-4EDD-9991-F09AFC82D1B8 Q33566687-FE654E26-BD46-4E88-8AA1-AE618844636D Q33683680-85B859CA-DAAB-4772-8FB7-BDFEA1545F00 Q34138308-14CE4BE4-3B31-470C-A25E-812C2AB3F4E8 Q34442771-E8C2865F-ED4F-4652-81A7-55DE98550924 Q34659512-2AB18C13-09C7-4AEC-9554-D462978F93D2 Q34776118-CCA5074C-3094-4E7D-83E1-564A433A1214 Q35067570-793187A2-5AE3-476F-BF6F-E8E32239EB8F Q35075820-E528941F-D218-45D8-8B25-5B31B67B6939 Q35101357-42CBE9FA-51AC-4BCB-BE0A-071D1AC1193E Q35678113-C6EFCA19-A9A7-45DE-9F96-D1C899173EA5 Q35760814-1F65DC97-FEE4-43FC-B724-F3DF5D077516 Q36451765-53FDB4AF-8628-43E2-9EF1-B349803A173C Q36582552-25D023D8-A2DE-4030-8883-917F28D51291 Q36977406-D0A95D1B-52BB-4309-B9FB-5EB855E468AB Q37146300-737DAD66-B6D5-4D61-84AD-E2F1822CD2FA Q37218978-FFC2D140-D41E-46BB-8122-C8CDE3792CD4 Q37636844-82D7E41A-3B21-4DD2-9771-6BEE9D35C381 Q37663252-84D84A47-9600-41E2-80E2-CDB646ADEA14 Q37697540-B4FA0AF9-A256-4379-BCF6-27D82A82BC48 Q37702586-CDDFF30B-CA6A-43E7-A88D-E7533C98F213 Q37886995-C86E90A6-6802-42F5-A4C2-E80A160B944C Q38089641-4A7C79D1-61AA-4905-9E36-DE17D79C8A00 Q38096413-9E3EDD56-CF36-4AAA-8AE3-BB25B32F4560 Q38104294-6CD6D6F2-999F-485B-9195-990A85BA6C97 Q38219290-BAF149A9-F834-4924-ADC7-308CFCE1620D Q38222512-CD323F7B-2BF7-43A2-9934-19297813C610 Q38291130-09732831-7805-4FB3-8A58-47F7BCD199AF Q38562067-7FA3D9D2-9F9C-4573-9751-A5A3C1C942D7

P2860

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

http://www.wikidata.org/entity/Q33809458

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Impact of KRAS, BRAF, PIK3CA m ...... of colorectal cancer patients

@ast

Impact of KRAS, BRAF, PIK3CA m ...... of colorectal cancer patients

@en

type

label

Impact of KRAS, BRAF, PIK3CA m ...... of colorectal cancer patients

@ast

Impact of KRAS, BRAF, PIK3CA m ...... of colorectal cancer patients

@en

prefLabel

Impact of KRAS, BRAF, PIK3CA m ...... of colorectal cancer patients

@ast

Impact of KRAS, BRAF, PIK3CA m ...... of colorectal cancer patients

@en

P1433

Q33809458-87C92CDC-4584-4958-8F4E-428C883A6770

P1476

Q33809458-1EAA7B6F-73BB-4109-87CB-FD08C1E29574

P2093

Q33809458-0B8DD759-F674-4510-ABF7-E52496F37B27

Q33809458-17049BC4-FF1F-4ACD-84E2-5043D7CF2525

Q33809458-1804437D-C3E9-4C90-9705-A11680D17B11

Q33809458-526F7EBC-3F38-43D9-A736-B3C46DE0AAA1

Q33809458-630B4C2F-1FEA-4C7A-88D8-AC128485D96B

Q33809458-8B38A62A-95DA-4D59-A563-2A16FD6814A4

Q33809458-8F9BBC38-F90D-4071-B741-3634BA400D73

Q33809458-B3E75811-775D-43DD-BABB-E0DD49C51DE5

Q33809458-C95D38F9-372F-4A88-B73C-50CA198D5B4D

Q33809458-D4A0D424-8E4D-4F51-80AB-D6BD6C8ADD02

P2860

Q33809458-010AC5C7-9E92-41B5-B082-6B9CD208F853

Q33809458-039BADBC-5FFB-494C-8843-DAED3D6A7BED

Q33809458-06C4795B-0516-4E30-97BE-BDF9EEEAF47C

Q33809458-0B47143A-D756-46D6-BBAA-8EF7BC085BEB

Q33809458-154B529E-1A17-433F-81C0-842EBC3B35B7

Q33809458-15DD6AD0-5711-4EB3-8831-60D3B51E19A9

Q33809458-1CC8F0C2-D5C2-48BA-BA4E-F8404DF151DB

Q33809458-24FD420C-465E-4714-9ED5-8DCFE793B1AA

Q33809458-2A570721-94F7-4D25-9067-1AE597E2404F

Q33809458-35CA7A19-28EB-4232-942C-6BA1D492F53C

P304

Q33809458-92594A77-43E6-419C-BBC0-CC6F7EE8D7C1

P31

Q33809458-959DC3DE-E0C6-4814-9B3A-DF61FA8F7D62

P356

Q33809458-CDE737DB-F99C-4F5F-8374-CC0B62E47DB0

P407

Q33809458-B6447216-8E1B-475C-B9BB-3A5C02756311

P433

Q33809458-DFF09D8E-00B7-4CA6-A319-988875395613

P478

Q33809458-4DFBBE23-3747-42C7-AC60-89DB6D0571C3

P577

Q33809458-09AE5DF8-418C-4ECC-900E-16EB2E734961

P5875

Q33809458-67D4865F-0CC5-4FAC-8282-304C7F5AF1D2

P698

Q33809458-0CC19E2C-82D4-4D29-8080-4199AEF947BF

P921

Q33809458-2C0AE54A-D9B5-4BD0-A088-92E39CA68DC2

Q33809458-D8A7C2F4-C95C-40C7-AB3B-ABA918253C1C

P932

Q33809458-91B4922A-76D8-44BC-A2B8-EFD7691A99D8

P356

JOURNAL.PONE.0015980

P1433

P1476

Impact of KRAS, BRAF, PIK3CA m ...... of colorectal cancer patients

@en

P2093

Aristea Kalikaki

http://www.w3.org/2001/XMLSchema#string

Chara Papadaki

http://www.w3.org/2001/XMLSchema#string

Dimitris Mavroudis

http://www.w3.org/2001/XMLSchema#string

Efstathios Stathopoulos

http://www.w3.org/2001/XMLSchema#string

Eleftheria Tsakalaki

http://www.w3.org/2001/XMLSchema#string

Fraga Pega

http://www.w3.org/2001/XMLSchema#string

Ippokratis Messaritakis

http://www.w3.org/2001/XMLSchema#string

John Souglakos

http://www.w3.org/2001/XMLSchema#string

Maria Sfakianaki

http://www.w3.org/2001/XMLSchema#string

Maria Trypaki

http://www.w3.org/2001/XMLSchema#string

P2860

Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

The genomic landscapes of human breast and colorectal cancers

P304

e15980

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0015980

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49800797

http://www.w3.org/2001/XMLSchema#string

P698

21283802

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3024325

http://www.w3.org/2001/XMLSchema#string